We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+14.65%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$262M
AUM Growth
+$34.4M
(+15%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
4.87%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
59
New
5
Increased
15
Reduced
23
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XENT
Intersect ENT, Inc
XENT
|
+$9.35M |
| 2 |
AKRX
Akorn Inc
AKRX
|
+$5.25M |
| 3 |
Halozyme
HALO
|
+$5.24M |
| 4 |
Heron Therapeutics
HRTX
|
+$5.03M |
| 5 |
Omnicell
OMCL
|
+$4.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$4.62M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
+$4.56M |
| 3 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$2.94M |
| 4 |
DOC
PHYSICIANS REALTY TRUST
DOC
|
+$2.9M |
| 5 |
LeMaitre Vascular
LMAT
|
+$2.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.96% |
| 2 | Energy | 2.6% |
| 3 | Communication Services | 1.68% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NXTM
26
DELISTED
NxStage Medical Inc.
NXTM
| $4.56M | 1.74% |
170,007
-77,008
| -31% | -$2.13M |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $4.48M | 1.71% |
3,804
-1,696
| -31% | -$1.73M |
|
|
MODN
28
DELISTED
MODEL N, INC.
MODN
| $4.4M | 1.68% |
420,750
+38,106
| +10% | +$371K |
|
29
Bio-Techne
TECH
$11.2B
| $3.88M | 1.48% |
152,808
-1,200
| -0.8% | -$31K |
|
30
BioMarin Pharmaceuticals
BMRN
$11.6B
| $2.77M | 1.06% |
31,592
-167
| -0.5% | -$14.9K |
|
31
Vertex Pharmaceuticals
VRTX
$121B
| $2.53M | 0.97% |
23,125
-100
| -0.4% | -$8.8K |
|
|
NSTG
32
DELISTED
NanoString Technologies, Inc.
NSTG
| $2.28M | 0.87% |
114,755
-1,021
| -0.9% | -$19.4K |
|
33
iShares Biotechnology ETF
IBB
$9.34B
| $2.08M | 0.79% |
21,291
-2,400
| -10% | -$230K |
|
34
Ionis Pharmaceuticals
IONS
$8.6B
| $2.02M | 0.77% |
50,189
+731
| +1% | +$32.8K |
|
35
Alkermes
ALKS
$8.22B
| $1.74M | 0.66% |
29,689
-30,844
| -51% | -$1.75M |
|
|
CELG
36
DELISTED
Celgene Corp
CELG
| $1.71M | 0.65% |
13,701
-96
| -0.7% | -$11.5K |
|
37
QuidelOrtho
QDEL
$1.14B
| $1.68M | 0.64% |
74,383
-897
| -1% | -$18.6K |
|
|
STRM
38
DELISTED
Streamline Health Solutions
STRM
| $1.67M | 0.64% |
109,063
+665
| +0.6% | +$12.5K |
|
|
XLVS
39
DELISTED
POWERSHARES S&P SMALLCAP HEALTH CARE PORTFOLIO
XLVS
| $1.38M | 0.53% |
17,285
| – | – |
|
40
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $1.36M | 0.52% |
18,241
| – | – |
|
|
TEAR
41
DELISTED
TearLab Corporation
TEAR
| $1.2M | 0.46% |
421,025
+84,956
| +25% | +$421K |
|
42
iShares US Medical Devices ETF
IHI
$3.13B
| $1.15M | 0.44% |
45,480
| – | – |
|
43
MacroGenics
MGNX
$235M
| $1.14M | 0.44% |
61,503
-332
| -0.5% | -$6.4K |
|
|
44
LeMaitre Vascular
LMAT
$2.32B
| $1.14M | 0.43% |
46,203
-113,740
| -71% | -$2.67M |
|
45
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $659K | 0.25% |
9,499
-2,537
| -21% | -$170K |
|
46
Sanofi
SNY
$103B
| $304K | 0.12% |
6,720
| – | – |
|
|
CEMI
47
DELISTED
Chembio diagnostics, Inc.
CEMI
| $294K | 0.11% |
55,452
-20,850
| -27% | -$121K |
|
48
Pfizer
PFE
$143B
| $293K | 0.11% |
9,020
| – | – |
|
49
Merck
MRK
$322B
| $273K | 0.1% |
4,500
| – | – |
|
50
Johnson & Johnson
JNJ
$618B
| $272K | 0.1% |
2,183
| – | – |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2017 Portfolio in Review
As of Q1 2017, First Light Asset Management held 59 positions worth $262M, up 15% from $228M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
First Light Asset Management deployed $12.8M of net new capital in Q1 2017, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was Intersect ENT, Inc: 667,504 shares worth $11.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 78% a quarter earlier, followed by Energy and Communication Services.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $4.62M trimmed.
- First Light Asset Management's largest Q1 2017 buy was Intersect ENT, Inc: 667,504 shares worth $11.4M.
- First Light Asset Management added most to Akorn Inc in Q1 2017, an estimated $5.25M increase.
- First Light Asset Management's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $4.62M.
- First Light Asset Management fully exited Aratana Therapeutics, Inc. in Q1 2017, selling an estimated $2.94M.
- First Light Asset Management's ten largest holdings make up 49% of its $262M portfolio in Q1 2017.
- First Light Asset Management opened 5 new positions and closed 6 in Q1 2017.
- First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $262M.
Based on First Light Asset Management's 13F filing for Q1 2017, filed 15 May 2017.